Type(s) of chemotherapy-Protocols (combined treatment) Posts on Medivizor
Navigation Menu

Type(s) of chemotherapy-Protocols (combined treatment) Posts on Medivizor

Evaluating the risk of heart complications after anthracycline treatment for patients with DLBCL or FL

Posted by on Nov 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk of developing congestive heart failure (CHF; the muscle of the heart becomes weak and does not pump blood efficiently) in patients with non-Hodgkin’s lymphoma (NHL) after first-line chemoimmunotherapy. This study concluded that treatment containing anthracyclines was associated with a significantly higher...

Read More

Combo of taxane + bevacizumab + capecitabine is not recommended in metastatic breast cancer

Posted by on Feb 16, 2015 in Breast cancer | 0 comments

In a nutshell The authors studied the efficacy of taxanes (class of drugs including paclitaxel [Taxol] and docetaxel [Taxotere]) plus bevacizumab (Avastin) with or without capecitabine (Xeloda) in treating metastatic breast cancer.  Some background Bevacizumab has been studied for the treatment of breast cancer that is metastatic (that...

Read More

Disease-free survival in breast cancer patients is increased by adding paclitaxel to FAC chemotherapy

Posted by on Jul 15, 2013 in Breast cancer | 0 comments

In a nutshell In this study researchers examined the effect of a specific chemotherapy combination on disease-free survival in patients with node negative breast cancer. FAC treatment was compared to FAC treatment plus paclitaxel (FACwP). Some background A combination of the drugs fluorouracil (efudex), doxorubicin (doxil), and cyclophosphamide...

Read More

The link between tumor response 8 weeks into the treatment and overall survival in metastatic breast cancer patients treated with first-line chemotherapy

Posted by on Apr 21, 2013 in Breast cancer | 0 comments

In a nutshell The aim of this article was to determine if the initial shrinking of tumors due to combined chemotherapy is correlated with overall survival (OS) in patients with metastatic breast cancer (MBC – spread to other organs). Some background OS (survival at the end of the treatment) is the best parameter to evaluate treatment...

Read More

Addition of Aflibercept to FOLFIRI improves survival rates in patients previously treated with Oxaliplatin

Posted by on Mar 24, 2013 in Colorectal cancer | 0 comments

In a nutshell This study investigated the use of the chemotherapy regimen known as FOLFIRI with or without the addition of Aflibercept (Zaltrap) to treat metastatic colorectal cancer.  Results showed that adding Aflibercept significantly increased the length of time patients survive and the length of time they survive without any disease...

Read More

Chemotherapy Treatments For Triple-Negative Breast Cancer

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

This paper reviews chemotherapy options for triple-negative breast cancers. Breast cancer cells express 3 main receptors that can be targeted with therapy: Estrogen receptors (ER), Progesterone receptors (PR) and HER2. Triple-negative breast cancers (TNBCs) do not express these 3 receptors and make up approximately 15% of breast cancers. Such tumors do...

Read More